Diagnos Inc., a Canadian corporation specializing in early detection of critical health issues through Artificial Intelligence-based technology, has entered into an agreement with Investor Brand Network for corporate communication and awareness services. The engagement, effective January 10, 2026, involves monthly compensation of US$6,400 payable in advance from the company's funds and remains subject to acceptance by the TSX Venture Exchange. The partnership with IBN is designed to help Diagnos refine and strengthen its market awareness profile with the objective of maximizing shareholder value.
According to the announcement, IBN is acting at arm's length from Diagnos and holds no direct or indirect interest in the corporation's securities. This arrangement positions Diagnos to leverage specialized communications expertise as it continues developing its AI-driven healthcare solutions. Diagnos focuses specifically on early detection of critical eye-related health problems through its technology platform. By leveraging Artificial Intelligence, the company aims to provide healthcare clinicians with enhanced diagnostic tools that can improve accuracy, streamline workflows, and ultimately lead to better patient outcomes globally.
The engagement with Investor Brand Network represents a strategic move for Diagnos as it seeks to increase visibility within investment communities. IBN operates as part of a broader network of over 75 brands that provide comprehensive corporate communications solutions, including wire-grade press release syndication, article distribution to thousands of outlets, enhanced press release services, and social media distribution to millions of followers. These services are designed to help companies like Diagnos reach diverse audiences including investors, journalists, and the general public.
Additional information about the company's operations and financial disclosures is available through its corporate website at https://www.diagnos.com and through regulatory filings at https://www.sedarplus.com. For investors seeking current information about Diagnos, the company maintains a newsroom where updates are regularly posted at https://ibn.fm/DGNOF. This corporate communications initiative comes as Diagnos continues to advance its AI technology for healthcare applications, positioning the company for potential growth through increased market awareness and investor engagement.
